Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.595 AUD | -2.46% | -0.83% | -16.78% |
May. 10 | Transcript : 4DMedical Limited - Special Call | |
May. 09 | 4DMedical's CT-Based Ventilation Product Secures US Medical Reimbursement for Scans; Shares Rise 5% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.78% | 160M | - | ||
+11.91% | 227B | B | ||
+15.46% | 197B | B- | ||
+18.58% | 141B | B- | ||
+30.36% | 110B | A- | ||
+0.65% | 64.15B | A- | ||
+17.74% | 53.72B | B+ | ||
+5.82% | 51.75B | B+ | ||
+11.23% | 45.2B | A | ||
+5.73% | 37.37B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4DX Stock
- Ratings 4DMedical Limited